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Abstract
Background
Sanger sequencing, still the standard technique for genetic testing in most diag-
nostic laboratories and until recently widely used in research, is gradually being
complemented by next-generation sequencing (NGS). No single mutation
detection technique is however perfect in identifying all mutations. Therefore,
we wondered to what extent inconsistencies between Sanger sequencing and
NGS affect the molecular diagnosis of patients. Since mutations in SCN1A, the
major gene implicated in epilepsy, are found in the majority of Dravet
syndrome (DS) patients, we focused on missed SCN1A mutations.
Methods
We sent out a survey to 16 genetic centers performing SCN1A testing.
Results
We collected data on 28 mutations initially missed using Sanger sequencing. All
patients were falsely reported as SCN1A mutation-negative, both due to techni-
cal limitations and human errors.
Conclusion
We illustrate the pitfalls of Sanger sequencing and most importantly provide
evidence that SCN1A mutations are an even more frequent cause of DS than
already anticipated.
Introduction
When it comes to genetic screenings, Sanger sequencing
has long been considered the gold standard and is still
widely performed. However, next-generation sequencing
(NGS) is becoming steadily implemented nowadays, both
in research and in clinical diagnostic settings. Whereas
Sanger sequencing targets only one gene at a time,
making it a very time and cost-consuming method, NGS
technologies can analyze a set of genes, an exome, or even
a genome in a single sequencing run. This enormous
advantage has led to the widespread implementation of
different NGS platforms in genetic centers (Sisodiya
2015). It is well-known that no single mutation detection
technique is perfect in identifying all the mutations.
Therefore, we wondered to what extent negative findings
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on Sanger sequencing turn out to be false negative when
subsequently analyzed by NGS. To answer this question,
we focused our study on screenings of the SCN1A gene
(OMIM: #152389) in Dravet syndrome (DS), one of the
genetically most homogeneous epilepsy syndromes.
DS is among the best defined and most extensively
studied entities within the epileptic encephalopathies.
Clinically, the disease is characterized by a seizure onset in
the first year of life, usually around six months. Seizures at
onset are fever sensitive, and mostly consist of generalized
or unilateral, often prolonged, clonic, and tonic–clonic sei-
zures. As the disease progresses, afebrile seizures co-occur,
and other seizure types such as myoclonic seizures, atypical
absences, and focal seizures become more prominent
(Dravet 2011). Seizures usually are resistant to currently
available antiepileptic drugs. The development of patients
with DS is initially normal. During the second year of life
however, developmental delay and other neurological
defects become apparent (Brunklaus et al. 2012).
The most important gene implicated in DS is SCN1A,
encoding the alpha subunit of the neuronal voltage-gated
sodium channel Nav1.1. About 70% to 80% of DS patients
are shown to carry an SCN1A mutation of which 90%
occur de novo (Claes et al. 2001; Depienne et al. 2009).
Single nucleotide substitutions, small indels, and even
whole gene deletions have been reported with at least 1257
different mutations described to date (Suls et al. 2006;
Zuberi et al. 2011; Meng et al. 2015). These mutations
occur randomly throughout the gene, without the presence
of mutational hotspots. Recently, mutations in several
other genes including PCDH19, GABRG2, CHD2, and
HCN1 have been associated with a DS phenotype. How-
ever, each of these genes only has a small contribution.
SCN1A mutations can also be found in a few other epi-
lepsy syndromes that show some clinical similarities to
DS, such as myoclonic atonic epilepsy (MAE) and genetic
epilepsy with febrile seizures plus (GEFS+). The mutation
yield in these syndromes is however much lower, ranging
from a few percent up to 10% (Hirose et al. 2013).
Despite the significant contribution of genetic alter-
ations in SCN1A to DS, a subset of patients remain
without a genetic diagnosis after testing of SCN1A with
Sanger sequencing. These patients may harbor muta-
tions in one of the “minor” Dravet genes but could
also represent SCN1A false-negative cases that are carry-
ing an SCN1A mutation missed by Sanger sequencing.
Within our EuroEPINOMICS-RES consortium, we per-
formed whole-exome sequencing (WES) on 31 DS trios
(patient and healthy parents; cohort previously
described (Syrbe et al. 2015)) identifying SCN1A muta-
tions in eight patients considered SCN1A mutation-
negative upon Sanger screening (unpublished data).
This observation shows the limitations of Sanger
sequencing, but most importantly indicates that SCN1A
mutations are an even more frequent cause of DS than
is generally accepted.
After our prospective EuroEPINOMICS-RES consor-
tium study we conducted an additional retrospective
study to collect additional information on missed SCN1A
mutations and explored why all these mutations were
originally missed.
Materials and Methods
The study was approved by the local ethics committees of
participating centers. The protocol and procedures
employed were reviewed and approved by the appropriate
institutional review committee. Informed consent was
obtained for the patients described in this study. The fol-
lowed procedures were in accordance with the ethical
standards of the responsible committees on human exper-
imentation and with the Helsinki Declaration of 1975, as
revised in 2008.
We sent out a survey to 16 genetic centers performing
SCN1A screening on a diagnostic and/or research basis, to
collect information on SCN1A mutations (RefSeq
NM_001165963.1) that were searched for by Sanger
sequencing, but were only subsequently identified by NGS.
This study was broader than DS and included all pheno-
types related to SCN1A. In order to compare the results of
these genetic tests, we decided to only analyze detection
errors of point mutations or small insertions or deletions.
Partial/whole gene deletions and occasionally duplications
of SCN1A are also a well-documented cause of DS. These
structural alterations can be missed by Sanger sequencing
and may undoubtedly contribute to the group of SCN1A
false-negative cases. This was confirmed in the EuroEPI-
NOMICS-RES cohort where testing with array-CGH
detected two deletions in the remaining 23 SCN1A-nega-
tive patients (unpublished data). In the retrospective
study, we did not include copy number variants since call-
ing these variants from NGS data is still challenging and
clear comparisons between the results of the techniques
can thus not be made. With the questionnaire, we specifi-
cally asked for information on the sequencing techniques,
the reasons for missing the mutation, the setting (diagnos-
tic vs. research), and the date of the screening. All muta-
tions have been submitted to the SCN1A database (http://
www.gzneurosci.com/scn1adatabase/index.php).
Results
We received a response from 16 different genetic centers,
of which 13 had one or more patients to include. In the
retrospective study, we collected information on 20 addi-
tional patients harboring an SCN1A mutation that was
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missed by Sanger sequencing but confirmed by NGS and
one patient in whom an SCN1A mutation was detected
by Sanger sequencing that was missed in a WES study
looking for modifiers (Table 1). Eighteen patients were
diagnosed with DS, two other patients presented a pheno-
typically related epilepsy syndrome (GEFS+, MAE) and
one patient had an epileptic encephalopathy without fur-
ther phenotypical information (Table 1). Seven of the
patients have previously been reported (patient 2, 16, 17,
18, 19, 20, 29) (Table 1).
When comparing the technologies, 28 mutations were
detected using NGS after prior screening with Sanger
sequencing was reported to be negative. One mutation
was initially found by Sanger sequencing but subsequent
WES (aiming to investigate additional genetic modifiers)
failed to identify the mutation. Reasons for missing these
mutations can be classified into three categories (Table 2):
mutations were missed due to (1) human errors, (2) tech-
nical problems of the screening technique, and (3)
unknown reasons.
The most frequent reason for reporting false-negative
results were human errors (19/29; 66%). In retrospect, for
nine patients, the mutation was present in the Sanger
traces, but was simply overlooked by the person perform-
ing the initial analysis. Problems with primer design led
to false-negative results in four patients. The medical
report of one patient erroneously stated that he was
sequenced although he never was; a sample switch
occurred for one patient; one patient was assigned the
wrong sequencing data; for one the Sanger sequencing
results were of bad quality so the sequencing should have
been repeated; and for another patient, the mutation was
positioned eight base pairs into the intron and was there-
fore considered not significant and thus not mentioned in
the diagnostic report. Finally, one patient had an intronic
deletion leading to misalignment of the reads and conse-
quently uninterpretable data.
In three patients (10%), technical problems led to
missing the mutations. One mutation was not identified
in the Sanger traces due to the use of an excessively high
primer annealing temperature, but was detected by WES
and confirmed in a second Sanger sequencing run at a
lower temperature. For one patient, the peak of the muta-
tion in the electropherogram was too low to be called as
a variant by the analysis software. A first WES run on this
sample suggested mosaicism (49 reference reads vs. 18
variant reads), and this was confirmed by a second WES
run (169 reference reads vs. 81 variant reads). The muta-
tion detected by Sanger but subsequently missed by WES
was an A>T substitution lying in a stretch of adenine
nucleotides, creating a long homopolymer knowing to
cause problems in variant calling (both false-positive and
false-negative calls) using NGS sequencing.
For the remaining seven patients, we could not trace
the original sequencing reports and were thus unable to
identify the exact reason for mutation detection failure.
Discussion
When comparing sequencing techniques, our data show
that Sanger sequencing resulted in 28 false-negative results
while NGS missed one mutation. First of all, it should be
noted that these numbers probably give an incorrect
impression of the reliability of the different techniques,
since our retrospective analysis creates an ascertainment
bias toward patients initially screened by Sanger sequenc-
ing. Although NGS is the logical next step when Sanger
sequencing is negative, few patients will undergo Sanger
sequencing after a negative NGS screening, unless there is
evidence of low coverage of a particular gene or a partic-
ularly convincing phenotype.
Both techniques clearly have their own technical limita-
tions, as illustrated in this study. NGS is known to be supe-
rior to Sanger sequencing for the detection of low levels of
mutant allele, as seen in mosaicism. A probable mosaic
mutation was indeed first missed by Sanger sequencing, but
subsequently detected by WES in one patient in this study
(patient 21). The importance of germline and somatic
mosaicism is well established in a broad range of diseases,
including DS (Vadlamudi et al. 2010), and highlights the
usefulness of high coverage NGS techniques for mosaic
mutation detection. A major weakness of NGS on the other
hand is the sequencing of stretches of the same nucleotide,
which can lead to homopolymer-associated insertion and
deletion errors due to the nonlinear light response gener-
ated by the nucleotide stretches (patient 22). Another dis-
advantage of NGS is the use of relatively short reads,
although read lengths are increasing steadily with advanc-
ing NGS techniques. Short reads can lead to problems with
mapping quality, especially in repeat regions, which in turn
can result in misalignments and misinterpretation of the
data (Stranneheim and Lundeberg 2012).
Our study further showed that the majority (19/29) of
mutations were missed due to human errors, which in
most cases could have been prevented by applying rigor-
ous quality controls. Sample handling and allocation
remain error-prone steps independent of the sequencing
technology. In this context, the use of a well-functioning
laboratory information management system (LIMS) is
crucial. Keeping track of all the processes and logging
every detail may seem very labor intensive, but might
eventually save the costs of a potential redundant NGS
experiment. In recent years, strict quality control
procedures and criteria, including the use of LIMS, have
been developed for diagnostic genetic laboratories, and
are expected to result in a reduction of human errors.
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Also the analysis/interpretation process is prone to errors
that are more difficult to eradicate. Errors resulting from
visual inspection of Sanger traces can be circumvented by
using automated variant calling. Errors related to primer
design can be overcome by a more careful control of
parameters used in software for primer design. Recent
years have also brought us more sophisticated in silico
variant annotation and prediction tools that are greatly
aiding in our interpretation of variants, as illustrated for
the splice variant in patient 18. Our data show that most
mutations were missed during the early implementation
of SCN1A mutation testing in clinical practice. Neverthe-
less, even during the last two years false-negative results
were generated in a highly regulated diagnostic setting,
which shows that there is still room for improvement of
quality control (Table 1).
Table 1. Genetic and clinical information of the SCN1A mutations reported in this study as well as the setting and the date the samples were
screened.
Patient
Mutation
Inheritance Novel6 Phenotype
Setting
negative
screening
Setting
positive
screening
Date
negative
screening
Date
positive
screeningcDNA Protein
11 c.1121C>A p.Ser374Tyr De novo Yes DS Research Research 2012 2012
22 c.664C>T p.Arg222* De novo No DS Research Research 2006 2012
3 c.4002+1G>A De novo No DS Diagnostic Diagnostic 2013 2014
4 c.4284+1G>A De novo No DS Diagnostic Research 2007 2013
5 c.1178G>A p.Arg393His De novo No DS Diagnostic Research 2009 2011
6 c.5269G>A p.Gly1757Arg De novo Yes DS Diagnostic Research 2010 2013
7 c.5656C>T p.Arg1886* De novo No DS Diagnostic Research 2010 2013
8 c.53_55delCCA p.Thr18del Unknown Yes DS Diagnostic Diagnostic 2010 2015
9 c.602+1G>C Unknown Yes DS Diagnostic Diagnostic 2010 2015
101 c.5461C>T p.Gln1821* De novo No DS Research Research 2011 2013
11 c.379C>T p.His127Tyr De novo Yes GEFS+ Diagnostic Research 2007 2013
12 c.302G>A p.Arg101Gln De novo No DS Diagnostic Diagnostic 2013 2015
131 c.4853-1G>A De novo Yes DS Research Research 2011 2013
141 c.3439G>T p.Glu1147* De novo No DS NA Research NA 2012
15 c.302G>A p.Arg101Gln De novo No DS Diagnostic Research 2007 2013
163 c.5195C>T p.Pro1732Leu De novo No DS Diagnostic Research 2010 2013
174 c.2044-1G>A De novo No DS Research Research 2002 2011
183,1 c.2590-8T>G De novo No DS Diagnostic Research 2010 2013
192 c.1178G>A p.Arg393His De novo No DS Diagnostic Research 2009 2011
205,1 c.3452C>G p.Ser1151* De novo No DS Research Research 2010 2012
21 c.4889T>G p.Val1630Gly De novo Yes DS Diagnostic Research 2011 2013
22 c.2589+3A>T De novo No DS Research Research 2013 2005
231 c.4786C>T p.Arg1596Cys De novo No DS Diagnostic Research 2008 2013
241 c.5347G>A p.Ala1783Thr De novo No DS Research Research 2010 2012
25 c.5536_5539delAAAC p.Lys1846Serfs*11 Unknown No Unspecified
EE
Diagnostic Research 2008 2012
26 c.5771delG p.Arg1924Leufs*8 De novo Yes DS Diagnostic Diagnostic 2014 2014
27 c.4573C>T p.Arg1525* De novo No MAE Diagnostic Diagnostic 2006 2013
28 c.1129C>T p.Arg377* Absent in
mother,
father not
tested
No DS Research Research 2004 2013
294 c.383C>A p.Ser128* De novo No DS Diagnostic Diagnostic 2011 2011
DS: Dravet syndrome; EE: epileptic encephalopathy; GEFS+: genetic epilepsy with febrile seizures plus; MAE: myoclonic atonic epilepsy; NA: not
applicable; WES: whole-exome sequencing. Accession number for SCN1A: RefSeq NM_001165963.1, NP_001159435.1. Seven patients have pre-
viously been reported.
1These eight patients are part of the EuroEPINOMICS-RES cohort.
2Lemke et al., 2012.
3Bayat et al., 2015.
4Carvill et al., 2014.
5Gaily et al., 2013.
6Based on the SCN1A database (http://www.gzneurosci.com/scn1adatabase/index.php) and the published papers mentioned in this manuscript.
461ª 2016 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
T. Djemie et al. The Story of Missed SCN1A Mutations
Identifying SCN1A mutations in patients supposed to
be SCN1A-negative is not a unique observation of our
study but has been described previously. Carvill et al.
reported three mutations in 13 patients with DS in whom
a previous SCN1A screening turned out negative (Carvill
et al. 2014). Lemke et al. described two mutations in a
cohort of 33 patients with diverse epilepsy phenotypes
(Lemke et al. 2012), Bayat et al. mentioned two patients
with DS who initially tested negative upon SCN1A screen-
ing (Bayat et al. 2015) and Gaily et al. reported one such
patient (Gaily et al. 2013). Finding a mutation in pre-
screened and so-called mutation-negative patients is also
not limited to SCN1A, nor the epilepsy field. For exam-
ple, Klein and colleagues described five kindreds with
inherited polyneuropathy in whom WES identified known
pathogenic mutations that were initially overlooked by
Sanger sequencing, showing this phenomenon to be a
general concern for genetic diagnostics (Klein et al. 2014).
In total, we collected 29 SCN1A mutations in DS
patients erroneously reported as mutation-negative. This
illustrates that the frequency of SCN1A mutations in DS
is still underestimated and higher than the reported 80%.
The identification of an SCN1A mutation in 32% (10/31)
of DS patients from our “SCN1A-negative” EuroEPI-
NOMICS-RES consortium study clearly shows that DS is
even more genetically homogenous than previously
anticipated. That 13 of the 16 participating centers con-
tributed false-negative cases indicates that missing SCN1A
mutations occurs regularly. However, the exact frequency
could not be determined as in the prospective EuroEPI-
Table 2. Overview of the different reasons that SCN1A mutations were missed in a genetic screening.
Patient Negative screening Positive screening Reason that the mutation was missed
Human error
1 Sanger NGS: WES Missed by the person performing the mutation analysis (visual inspection of Sanger traces)
21 Sanger NGS: Gene panel Missed by the person performing the mutation analysis (visual inspection of Sanger traces)
3 Sanger NGS: Gene panel Missed by the person performing the mutation analysis (visual inspection of Sanger traces)
4 Sanger NGS: WES Missed by the person performing the mutation analysis (visual inspection of Sanger traces)
5 Sanger NGS: WES Missed by the person performing the mutation analysis (visual inspection of Sanger traces)
6 Sanger NGS: Gene panel Missed by the person performing the mutation analysis (visual inspection of Sanger traces)
7 Sanger NGS: Gene panel Missed by the person performing the mutation analysis (visual inspection of Sanger traces)
8 Sanger NGS: Gene panel Missed by the person performing the mutation analysis (visual inspection of Sanger traces)
9 Sanger NGS: Gene panel Missed by the person performing the mutation analysis (visual inspection of Sanger traces)
10 Sanger NGS: WES Error in the primer design: The mutation was located in the primer binding site
11 Sanger NGS: WES Error in the primer design: A polymorphism in the primer led to mono-allelic amplification
12 Sanger NGS: Gene panel Error in the primer design: A polymorphism in the primer led to mono-allelic amplification
13 Sanger NGS: WES Error in the primer design: The primer did not cover the whole amplicon (only one direction was sequenced)
14 Sanger NGS: WES The patient turned out not to be sequenced
15 Sanger NGS: WES Possible sample swap outside the lab
162 Sanger NGS: Gene panel Wrong sequencing data assigned to the patient
173 Sanger NGS: WES The traces were of bad quality so the Sanger should have been redone
182 Sanger NGS: Gene panel Not reported in the diagnostic report as the mutation is located eight base
pairs in the intron
191 Sanger NGS: Gene panel An adjacent intronic polymorphic deletion led to misalignment of the alleles and uninterpretable data
Technical error
204 Sanger NGS: WES The annealing temperature of the primers was too high for the polymerase
21 Sanger NGS: WES The mutated peak was too low
22 NGS: WES Sanger The mutation is located in a homopolymer stretch
Unknown reason
23 Sanger NGS: WES Unable to retrieve the Sanger traces
24 Sanger NGS: WES Unable to retrieve the Sanger traces
25 Sanger NGS: Gene panel Unable to retrieve the Sanger traces
26 Sanger NGS: Gene panel Unable to retrieve the Sanger traces
27 Sanger NGS: WES Unable to retrieve the Sanger traces
28 Sanger NGS: Gene panel Unable to retrieve the Sanger traces
NGS: next-generation sequencing; WES: whole-exome sequencing. Seven patients have previously been reported.
1Lemke et al., 2012.
2Bayat et al., 2015.
3Carvill et al., 2014.
4Gaily et al., 2013.
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NOMICS-RES study. Given the variability in data storage
procedures of the different genetic centers involved in this
study, we were unable to retrieve information on the total
number of SCN1A-negative patients that underwent a
genetic screening with a second technology.
Given the high genetic homogeneity of DS, first-line test-
ing for DS should be the search for an SCN1A mutation.
Whether this is performed using Sanger sequencing or
NGS (e.g., a gene panel with a high coverage of SCN1A)
seems to be of lesser importance as no technique is perfect
in identifying all the mutations. In case of a negative
SCN1A test in a patient with a convincing clinical suspicion
of DS, we recommend clinicians to discuss the need to use
a second genetic technique and analyze SCN1A in depth to
be absolutely sure that no mutation is present. It should
however be noted that despite the clear genotype–pheno-
type correlation between SCN1A mutations and DS, muta-
tions in several other genes have also been associated with
a DS phenotype (Depienne et al. 2009; Carvill et al. 2014;
Nava et al. 2014). Additionally, aside from these “missed”
coding mutations, we can expect that mutations in non-
coding regulatory regions of SCN1A and possibly also epi-
genetic factors affecting the gene might play a role in the
pathogenesis of DS. A negative SCN1A screening should
therefore not be considered as an exclusion factor for DS.
Finding a mutation and thus providing a clear etiologi-
cal diagnosis has major implications for the patient and
his/her family comprising not only issues related to prog-
nosis and family planning but also interventions toward a
more tailored treatment.
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